IRIDEX (NASDAQ:IRIX) Stock: Insider Shih-Yao David Lin Acquires 24,626 Shares

Posted by Stanley Muller on Oct 9th, 2026

IRIDEX Corporation (NASDAQ:IRIX – Get Free Report) major shareholder Shih-Yao David Lin bought 24,626 shares of the business’s stock in a transaction on Friday, November 14th. The shares were acquired at an average price of $0.88 per share, with a total value of $21,670.88. Following the transaction, the insider owned 808,340 shares of the company’s stock, valued at $711,339.20. The trade was a 3.14% increase in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Large shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

IRIDEX Price Performance

IRIX stock opened at $0.90 on Friday. The company’s 50 day simple moving average is $0.73 and its 200-day simple moving average is $0.95. IRIDEX Corporation has a 12 month low of $0.61 and a 12 month high of $1.65. The firm has a market capitalization of $15.78 million, a PE ratio of -4.49 and a beta of 0.67.

IRIDEX (NASDAQ:IRIX – Get Free Report) last issued its quarterly earnings data on Tuesday, August 18th. The medical equipment provider reported ($0.07) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.01) by ($0.06). The company had revenue of $12.57 million during the quarter, compared to analysts’ expectations of $13.59 million. As a group, sell-side analysts anticipate that IRIDEX Corporation will post -0.12 earnings per share for the current year.

Analysts Set New Price Targets

Separately, Weiss Ratings upgraded IRIDEX from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, October 2nd. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $3.00.

Read Our Latest Stock Analysis on IRIDEX

Key Headlines Impacting IRIDEX

Here are the key news stories impacting IRIDEX this week:

Positive Sentiment: Lin reported another purchase of 10,000 IRIX shares at an average price of $1.05, worth $10,500. The transaction increased his direct holdings to 735,561 shares. IRIDEX major shareholder buys 10,000 shares
Positive Sentiment: SEC disclosures show a sustained accumulation campaign by Lin, including purchases of 50,000 shares at $0.99, 40,114 shares at $1.00 and 80,000 shares at $1.00, along with numerous other transactions. Repeated buying by a major shareholder may signal confidence in IRIDEX’s longer-term prospects and can support momentum in a low-market-cap stock. IRIDEX major shareholder buys 50,000 shares
Positive Sentiment: Several institutional investors also increased positions, including Perkins Capital Management, Thompson Davis, and Renaissance Technologies. Institutions own approximately 20.1% of IRIDEX’s shares, providing additional ownership support, though their disclosed positions remain relatively small in dollar terms.
Neutral Sentiment: Trading in IRIX was temporarily halted under a Limit Up-Limit Down pause. The halt underscores unusually high volatility and the possibility of sharp price reversals when trading resumes.
Neutral Sentiment: Analyst sentiment remains mixed: one analyst rates the stock Buy and another Sell, resulting in a consensus Hold rating. The reported consensus price target is $3.00, but the limited coverage reduces its reliability.
Negative Sentiment: IRIDEX’s latest reported quarter remains a fundamental concern. The company posted a $0.07-per-share loss versus a $0.01 expected loss and revenue of $12.57 million versus the $13.59 million consensus estimate. Analysts expect a full-year loss of approximately $0.12 per share.

Institutional Trading of IRIDEX

A number of hedge funds have recently bought and sold shares of IRIX. United Capital Financial Advisors LLC purchased a new stake in IRIDEX in the 2nd quarter worth approximately $41,000. Weber Capital Management LLC ADV purchased a new position in shares of IRIDEX during the 2nd quarter worth $206,616. Diversify Advisory Services LLC purchased a new position in shares of IRIDEX during the 2nd quarter worth $30,000. Bank of New York Mellon Corp acquired a new stake in shares of IRIDEX during the second quarter worth $29,000. Finally, Renaissance Technologies LLC boosted its holdings in shares of IRIDEX by 6.7% during the first quarter. Renaissance Technologies LLC now owns 396,627 shares of the medical equipment provider’s stock worth $401,000 after purchasing an additional 25,067 shares during the last quarter. Institutional investors and hedge funds own 20.10% of the company’s stock.

IRIDEX Company Profile

(Get Free Report)

IRIDEX Corporation (NASDAQ: IRIX) develops and sells ophthalmic laser systems and related delivery devices used in the treatment of eye diseases. Its products are designed primarily for ophthalmologists treating glaucoma and retinal disorders, including diabetic retinopathy and other conditions affecting the retina.

The company’s portfolio includes laser systems such as the Cyclo G6 glaucoma laser platform and the IQ series of retinal photocoagulation lasers. IRIDEX also offers specialized probes and other delivery devices, including MicroPulse and transscleral cyclophotocoagulation technologies, which are intended to provide targeted treatment while limiting exposure to surrounding tissue.

Founded in 1989 and headquartered in Mountain View, California, IRIDEX serves eye-care professionals through a combination of direct sales and distributor relationships in the United States and international markets.